Searchable abstracts of presentations at key conferences in endocrinology

ea0016p308 | Endocrine tumours | ECE2008

ERCC1 expression in adrenocortical carcinoma: relationship with baseline characteristics and response to platinum-based chemotherapy

Ronchi Cristina L , Sbiera Silviu , Adams Patrick , Kraus Luthgard , Linss Heidi , Wortmann Sebastian , Willenberg Holger , Allolio Bruno , Fassnacth Martin

Adrenocortical carcinoma (ACC) is a malignant tumor with poor prognosis and no established therapy in advanced stage. Cisplatin is the most frequently used cytotoxic drug, but even combined with doxorubicin and etoposid, the response rate is <50%. Recently, it has been demonstrated that the excision repair cross complementing group 1 (ERCC1) plays a relevant role in the DNA repairing process, particularly in the correction of platinum-induced DNA adducts. Accordingly, ERCC...